Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT05247957 is registered in ClinicalTrials.gov with Hangzhou Cheetah Cell Therapeutics Co., Ltd as lead sponsor.

NCT NCT05247957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05247957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Hangzhou Cheetah Cell Therapeutics Co., Ltd
Phase
Not applicable
Overall status
Terminated
Start date
October 13, 2021
Completion date
December 20, 2022
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety and efficacy